Multimodal techniques for diagnosis and prognosis of Alzheimer's disease (original) (raw)

• Alzheimer, A. About a peculiar disease of the cerebral cortex [translation]. Alzheimer Dis. Assoc. Disord. 1, 7–8 (1987).
  Google Scholar
• Khachaturian, Z. S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42, 1097–1105 (1985).
  Article CAS Google Scholar
• Mirra, S. S. et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479–486 (1991).
  Article CAS Google Scholar
• Hyman, B. T. & Trojanowski, J. Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 1095–1097 (1997).
  Article CAS Google Scholar
• Crystal, H. et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682–1687 (1988).
  Article CAS Google Scholar
• Price, J. L. et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30, 1026–1036 (2009).
  Article Google Scholar
• Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357 (1997).
  Article CAS Google Scholar
• Evans, D. A. et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 262, 2551–2556 (1989).
  Article CAS Google Scholar
• Morris, J. C. & Price, J. L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J. Mol. Neurosci. 17, 101–118 (2001).
  Article CAS Google Scholar
• Gomez-Isla, T. et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491–4500 (1996).
  Article CAS Google Scholar
• Hardy, J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
  Article ADS CAS Google Scholar
• Morris, J. C. The clinical dementia rating (CDR). Current version and scoring rules. Neurology 43, 2412–2414 (1993).
  Article CAS Google Scholar
• Petersen, R. C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308 (1999).
  Article CAS Google Scholar
• Fox, N., Warrington, E. & Rossor, M. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 353, 2125 (1999). This paper reports how 5 of 28 cognitively normal individuals at risk of autosomal-dominant early-onset Alzheimer's disease developed “probable Alzheimer's disease” and could be distinguished by a mean rate of global cerebral atrophy of 1.5% per year from clinically stable subjects with a rate of 0.1% to 0.2% per year.
  Article CAS Google Scholar
• Carlson, N. E. et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 70, 828–833 (2008).
  Article CAS Google Scholar
• Devanand, D. P. et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68, 828–836 (2007).
  Article CAS Google Scholar
• Small, G. W. et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652–2663 (2006).
  Article CAS Google Scholar
• Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306–319 (2004). This first study of the tracer compound PIB in humans describes both the retention of PIB in areas of Alzheimer's-disease-affected brains known to contain amyloid and an inverse relationship between the PIB PET signal and cerebral glucose metabolism, measured by fluorodeoxyglucose PET.
  Article CAS Google Scholar
• Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446–452 (2006).
  Article CAS Google Scholar
• Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans. Ann. Neurol. 59, 512–519 (2006). This study illustrates an inverse relationship between mean cortical retention of PIB and cerebrospinal-fluid A β 42 concentrations among both demented and non-demented subjects, suggesting that brain amyloid deposition results in low cerebrospinal-fluid A β 42 and that amyloid imaging and cerebrospinal-fluid A β 42 might serve as antecedent biomarkers of preclinical Alzheimer's disease.
  Article CAS Google Scholar
• Morris J. C. et al. PIB imaging predicts progression to symptomatic Alzheimer's disease. Arch. Neurol. (in the press).
• Zhang, M. R. et al. Development of a new radioligand, _N_-(5-fluoro-2-phenoxyphenyl)-_N_-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for PET imaging of peripheral benzodiazepine receptor in primate brain. J. Med. Chem. 47, 2228–2235 (2004).
  Article CAS Google Scholar
• Vas, A. et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J. Neurol. Sci. 264, 9–17 (2008).
  Article CAS Google Scholar
• Edison, P. et al. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](_R_)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 32, 412–419 (2008).
  Article CAS Google Scholar
• Nakamura, S. et al. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 80, 419–425 (1990).
  Article CAS Google Scholar
• Hirvonen, J. et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin. Pharmacol. Ther. 85, 506–512 (2009).
  Article CAS Google Scholar
• Dickerson, B. C. & Sperling, R. A. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia 46, 1624–1635 (2008).
  Article Google Scholar
• Buckner, R. L. et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25, 7709–7717 (2005). In this paper, five in vivo neuroimaging methods are used to illustrate the similarities among the anatomical distributions of atrophy, reduced glucose metabolism and amyloid deposits seen in Alzheimer's disease, and of the default network, suggesting that young-adult brain activity and metabolism patterns may be conducive to cortical amyloid deposition.
  Article CAS Google Scholar
• Hirao, K. et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 28, 1014–1021 (2005).
  Article Google Scholar
• de Leon, M. J. et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc. Natl Acad. Sci. USA 98, 10966–10971 (2001).
  Article ADS CAS Google Scholar
• Chetelat, G. et al. Mild cognitive impairment — can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60, 1374–1377 (2003).
  Article CAS Google Scholar
• Kadir, A. et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann. Neurol. 63, 621–631 (2008).
  Article CAS Google Scholar
• Gusnard, D. A. & Raichle, M. E. Searching for a baseline: functional imaging and the resting human brain. Nature Rev. Neurosci. 2, 685–694 (2001).
  Article CAS Google Scholar
• Buckner, R. L., Andrews-Hanna, J. R. & Schacter, D. L. The brain's default network: anatomy, function, and relevance to disease. Ann. NY Acad. Sci. 1124, 1–38 (2008).
  Article ADS Google Scholar
• Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925–937 (2003).
  Article CAS Google Scholar
• Cirrito, J. R. et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo . Neuron 48, 913–922 (2005).
  Article CAS Google Scholar
• Brody, D. L. et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 321, 1221–1224 (2008).
  Article ADS CAS Google Scholar
• Motter, R. et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643–648 (1995).
  Article CAS Google Scholar
• Fagan, A. M. et al. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65, 176–183 (2009).
  Article CAS Google Scholar
• Tapiola, T. et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382–389 (2009).
  Article Google Scholar
• Fagan, A. M. et al. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343–349 (2007).
  Article Google Scholar
• Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228–234 (2006). This report illustrates the utility of cerebrospinal-fluid biomarkers A β 42 , tau and phosphorylated tau in predicting the progression of patients from mild cognitive impairment to dementia attributed clinically to Alzheimer's disease.
  Article CAS Google Scholar
• Li, G. et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69, 631–639 (2007).
  Article CAS Google Scholar
• Cairns, N. J. et al. PiB-PET detection of cerebral Aβ may lag clinical, cognitive, and CSF markers of Alzheimer's disease: a case report. Arch. Neurol. (in the press).
• Mehta, P. D., Pirttila, T., Patrick, B., Barshatzky, M. & Mehta, S. Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304, 102–106 (2001).
  Article CAS Google Scholar
• Vanderstichele, H. et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245–258 (2000).
  Article CAS Google Scholar
• Graff-Radford, N. R. et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64, 354–362 (2007).
  Article Google Scholar
• Mayeux, R. et al. Plasma amyloid β-peptide 1–42 and incipient Alzheimer's disease. Ann. Neurol. 46, 412–416 (1999).
  Article CAS Google Scholar
• Portelius, E. et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 7, 2114–2120 (2008).
  Article CAS Google Scholar
• Vandermeeren, M. et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbant assay. J. Neurochem. 61, 1828–1834 (1993).
  Article CAS Google Scholar
• Meyer-Luehmann, M. et al. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature 451, 720–724 (2008).
  Article ADS CAS Google Scholar
• Montine, T. J. et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am. J. Pathol. 155, 863–868 (1999).
  Article CAS Google Scholar
• Praticò, D., Lee, M.-Y.V., Trojanowski, J. Q., Rokach, J. & Fitzgerald, G. A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo . FASEB J. 12, 1777–1783 (1998).
  Article Google Scholar
• de Leon, M. J. et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to Alzheimer's disease. J. Neurol. 254, 1666–1675 (2007).
  Article CAS Google Scholar
• Pratico, D. et al. Increased 8,12-_iso_-iPF2α-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48, 809–812 (2000).
  Article CAS Google Scholar
• Montine, T. J. et al. No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann. Neurol. 48, 950 (2000).
  Article CAS Google Scholar
• Abe, T., Tohgi, H., Isobe, C., Murata, T. & Sato, C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J. Neurosci. Res. 70, 447–450 (2002).
  Article CAS Google Scholar
• Abraham, C. R., Selkoe, D. J. & Potter, H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52, 487–501 (1988).
  Article CAS Google Scholar
• Thal, D. R., Schober, R. & Birkenmeier, G. The subunits of α2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed α2-macroglobulin and interleukin 6 in Alzheimer's disease. Brain Res. 777, 223–227 (1997).
  Article CAS Google Scholar
• Zanjani, H. et al. Complement activation in very early Alzheimer disease. Alzheimer Dis. Assoc. Disord. 19, 55–66 (2005).
  Article CAS Google Scholar
• DeKosky, S. T. et al. Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann. Neurol. 53, 81–90 (2003).
  Article CAS Google Scholar
• Hye, A. et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042–3050 (2006).
  Article CAS Google Scholar
• Hu, Y. et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin. Appl. 1, 1373–1384 (2007).
  Article CAS Google Scholar
• Thambisetty, M. et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 255, 1712–1720 (2008).
  Article CAS Google Scholar
• Smyth, M. D. et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging 15, 609–614 (1994).
  Article CAS Google Scholar
• Loeffler, D. A. et al. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease. Neurobiol. Aging 18, 555–557 (1997).
  Article CAS Google Scholar
• Tan, Z. S. et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 68, 1902–1908 (2007).
  Article CAS Google Scholar
• Simard, A. R., Soulet, D., Gowing, G., Julien, J. P. & Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489–502 (2006).
  Article CAS Google Scholar
• Guerreiro, R. J. et al. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener. Dis. 4, 406–412 (2007).
  Article CAS Google Scholar
• Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med. 13, 1359–1362 (2007). This paper identified a panel of 18 signalling proteins in blood plasma that might be used to predict and diagnose early Alzheimer's disease. This work illustrates the potential of 'unbiased' screening of multiple analytes in biological fluids to identify early diagnostic and prognostic biomarkers for Alzheimer's disease.
  Article CAS Google Scholar
• Davidsson, P. et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13, 611–615 (2002).
  Article CAS Google Scholar
• Zhang, J. et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimer's Dis. 7, 125–133; discussion 173–180 (2005).
  Article CAS Google Scholar
• Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. & Lee, K. H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 61, 120–129 (2007).
  Article CAS Google Scholar
• Bateman, R. J. et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo . Nature Med. 12, 856–861 (2006). This report uses amyloid- β peptide species as an example to describe a novel technique that will facilitate the evaluation of disease-modifying treatments for Alzheimer's disease by measuring the production and clearance rates of proteins in the human central nervous system, following administration of a non-radioactive isotopically labelled amino acid (in this case leucine).
  Article CAS Google Scholar
• Bateman, R. J. et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann. Neurol. 66, 48–54 (2009).
  Article CAS Google Scholar
• Kauwe, J. S. et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 10, 13–17 (2009).
  Article CAS Google Scholar
• Craig-Schapiro, R., Fagan, A. M. & Holtzman, D. M. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 35, 128–140 (2009).
  Article CAS Google Scholar
• Sunderland, T. et al. Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J. Am. Med. Assoc. 289, 2094–2103 (2003).
  Article Google Scholar
• Welsh-Bohmer, K. A. & Johnson, S. in Handbook of Dementing Illnesses 2nd edn (eds Morris, J. C., Galvin, J. E. & Holtzman, D. M.) 59–87 (Taylor & Francis, 2006).
  Google Scholar